Stock Events

Stock Events

Eloxx Pharmaceuticals 

0
22
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q3 2023
Q2 2026
Next
-20.25
-13.69
-7.12
-0.56
Expected EPS
-0.55913
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-5.11MNet Income

Analyst Ratings

30.60Average Price Target
The highest estimate is 32.63.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 397.STU. It's not an investment recommendation.
Tesla
5
TSLA
Intel
5
INTC
NIO
5
NIO
AGNC Investment
4
AGNC

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for cystic fibrosis, a key area of focus for Eloxx Pharmaceuticals.
PTC Therapeutics
PTCT
Mkt Cap5.85B
PTC Therapeutics competes in the space of genetic disorders, including nonsense mutation-related conditions, directly overlapping with Eloxx's target market.
Sarepta Therapeutics
SRPT
Mkt Cap2.2B
Sarepta Therapeutics is involved in the development of RNA-targeted therapeutics, competing with Eloxx's approach to treat genetic diseases through read-through technologies.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals works on RNA interference (RNAi) therapeutics for the treatment of rare genetic diseases, competing with Eloxx's focus on genetic disorder treatments.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, making it a competitor in the genetic disease treatment market alongside Eloxx.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical focuses on enzyme replacement therapies for rare genetic disorders, competing with Eloxx's approach to treating similar conditions.
Ultragenyx Pharmaceutical
RARE
Mkt Cap2.52B
Ultragenyx Pharmaceutical targets rare and ultra-rare diseases with its drug development, overlapping with Eloxx's focus on rare genetic disorders.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is working on gene editing technologies, which could offer treatments for the same genetic disorders Eloxx is targeting.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine is involved in genome editing technology, representing a competitive approach to treating genetic diseases that Eloxx also aims to address.

About

Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
Show more...
CEO
Sumit Aggarwal
Employees
7
Country
United States
ISIN
US29014R1032
WKN
000A42B0D

Listings

MU
DE
397.MU
STU
DE
397.STU
XNAS
US
ELOX
F
DE
J36.F

0 Comments

Share your thoughts

FAQ

What is Eloxx Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Eloxx Pharmaceuticals stocks are traded under the ticker 397.STU.
When is the next Eloxx Pharmaceuticals earnings date?▼
Eloxx Pharmaceuticals is going to release the next earnings report on November 11, 2026.
What were Eloxx Pharmaceuticals earnings last quarter?▼
397.STU earnings for the last quarter are -0.57 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Eloxx Pharmaceuticals revenue for the last year?▼
Eloxx Pharmaceuticals revenue for the last year amounts to 0 EUR.
What is Eloxx Pharmaceuticals net income for the last year?▼
397.STU net income for the last year is -5.11M EUR.
How many employees does Eloxx Pharmaceuticals have?▼
As of September 04, 2026, the company has 7 employees.
In which sector is Eloxx Pharmaceuticals located?▼
Eloxx Pharmaceuticals operates in the Health & Wellness sector.
When did Eloxx Pharmaceuticals complete a stock split?▼
The last stock split for Eloxx Pharmaceuticals was on December 02, 2022 with a ratio of 1:40.
Where is Eloxx Pharmaceuticals headquartered?▼
Eloxx Pharmaceuticals is headquartered in ARLINGTON, United States.